ALSF Childhood Cancer Research Grants
With your support, we have been able to fund outstanding research, leading toward cures and improved quality of life for children with cancer. Browse through more than 1,500 funded projects below.
Use the search tool to refine your results. You can also click on a heading to sort by project title, institution name, or year the grant was awarded. Click on the project title to read more information.
You can learn about ALSF's grant review process here.
ALSF Funded Research Projects
| Project Title | Institution / Principal Investigator(s) | Grant Type | Year | State |
|---|---|---|---|---|
| Circumventing Pediatric Solid Tumor Microenvironment Resistance by Combinatorial CAR NK and Immunomodulating Therapy | New York Medical College / Mitchell Cairo, MD | Reach Grants | 2023 | New York |
| Immunoglobulin High-Throughput Sequencing for Refining Risk Stratification in Infant B-ALL | University of Rochester / Carol Fries Simpson, MD | Reach Grants | 2023 | New York |
| Reversing Feedback Immunosuppression during Oncolytic Virotherapy of Pediatric High Grade Glioma | Augusta University Research Institute, Inc. / Bangxing Hong, PhD | Reach Grants | 2023 | Georgia |
| Feasibility Study of Dual Inhibition of MDM2 and Tubulin in Treatment of AML | Emory University / Muxiang Zhou, MD | Reach Grants | 2023 | Georgia |
| Identification of Aberrantly Methylated Differentially Expressed Genes to Distinguish High- vs. Low-Risk Retinoblastoma | Children’s Hospital Los Angeles / Jesse Berry, MD | Reach Grants | 2023 | California |
| Novel Therapy for Pediatric Leukemia Patients with NUP98 Translocations | The Regents of the University of Michigan / Jolanta Grembecka, PhD | Reach Grants | 2022 | Michigan |
| Mechanistic and Therapeutic Development of ATM as a Tumor Cell Selective Target for Radiosensitization in H3K27M DMG | The Regents of the University of Michigan / Meredith Morgan, PhD & Daniel Wahl, MD/PhD | Reach Grants | 2022 | Michigan |
| Enhancing TKI Therapy in Ph-Like Leukemia | The Regents of the University of California, Irvine / David Fruman, PhD | Reach Grants | 2022 | California |
| IND-Enabling Studies for WNTinib, a Novel Selective Therapeutic for CTNNB1 Mutant Hepatoblastomas | Icahn School of Medicine at Mount Sinai / Ernesto Guccione, PhD & Josep Llovet, MD & Arvin Dar, PhD | Reach Grants | 2021 | New York |
| Optimization of Drug Efflux and Brain Clearance to Improve CED of Targeted Therapy to H3K27M DMG | Mayo Clinic / David Daniels, MD/PhD | Reach Grants | 2021 | Minnesota |
| Stapled Peptide PROTAC: A 3-in-1 Treatment for Pediatric Solid Tumors | Dana-Farber Cancer Institute / Loren Walensky, MD/PhD | Reach Grants | 2021 | Massachusetts |
| Dual PTK7/GD2 Gamma Delta CAR T Cell Therapy for Neuroblastoma | Emory University / Kelly Goldsmith, MD & H. Trent Spencer, PhD & Chris B. Doering, PhD | Reach Grants | 2021 | Georgia |
| Novel Genomic Diagnostics for Intracranial Germ Cell Tumors | Connecticut Children’s Medical Center Foundation, Inc. / Ching Lau, MD/PhD | Reach Grants | 2021 | Connecticut |
| Preclinical Development of a First-in-Class PCNA Inhibitor for Treating Neuroblastoma | City of Hope National Medical Center / Linda Malkas, PhD | Reach Grants | 2019 | California |
| Optimizing TCRαβ+/CD19+-depleted haploidentical HSCT for ALL using donor-derived genome-edited CAR T cells | Stanford University School of Medicine / Alice Bertaina, MD/PhD | Reach Grants | 2019 | California |
| Targeting a Novel Epigenetic Signature in Diffuse Intrinsic Pontine Gliomas | New York University School of Medicine / Danny Reinberg, PhD | Reach Grants | 2019 | New York |
| Generation of CMV-specific CD19 CAR T cells Using Cytokine Capture Followed by Lentiviral Transduction and Expansion | Research Institute at Nationwide Children's Hospital / Margaret Lamb, MD | Reach Grants | 2019 | Ohio |
| Multivalent Nanomedicine to Treat High-Risk Pediatric Solid Tumors | Children’s Hospital of Philadelphia / Garrett Brodeur, MD | Reach Grants | 2019 | Pennsylvania |
| Immuno-therapeutic Targeting of CD56 in CBA2T3/GLIS2-AML in Children | Fred Hutchinson Cancer Research Center / Soheil Meshinchi, MD/PhD | Reach Grants | 2018 | Washington |
| Identifying a Therapeutic Partner for TAK228 for Pediatric Phase II Brain Tumor Studies | The Johns Hopkins University School of Medicine / Eric H. Raabe, MD/PhD | Reach Grants | 2018 | Maryland |
| Epigenetic Targeted Therapy and Resistance in Pediatric Rhabdoid Tumor | Ann & Robert H. Lurie Children’s Hospital of Chicago / Rintaro Hashizume, MD/PhD | Reach Grants | 2018 | Illinois |
| Therapeutic Targeting of PGBD5-induced DNA Repair Dependency in Pediatric Solid Tumors | Memorial Sloan-Kettering Cancer Center / Alex Kentsis, MD/PhD | Reach Grants | 2017 | New York |
| Targeting Chondroitin Sulphate Proteoglycan 4 (CSPG4) in Glioblastoma | University of North Carolina / Gianpietro Dotti, MD & Barbara Savoldo, MD/PhD | Reach Grants | 2017 | North Carolina |
| Phase I Study of Lentivirus Engineered Autologous AML Cells Expressing IL-12 in Children and Young Adults with Relapsed AML | Children’s Hospital of Wisconsin - Milwaukee / Michael Burke, MD & Jeffrey Medin, MD/PhD | Reach Grants | 2017 | Wisconsin |
| Astatine-211 Meta-Astatobenzylguanidine ([211At]MABG) Targeted Radiotherapy for Disseminated Neuroblastoma | Children’s Hospital of Philadelphia / John Maris, MD | Reach Grants | 2016 | Pennsylvania |
| DFMO Synergy with Chemo-immunotherapy to Eradicate MYC-Driven Neuroblastoma | Children’s Hospital of Philadelphia / Michael Hogarty, MD | Reach Grants | 2016 | Pennsylvania |
| LSD1 Inhibition to Treat T-cell Acute Lymphoblastic Leukemia/Lymphoma | University of Virginia, School of Medicine / Michael Engel, MD/PhD | Reach Grants | 2016 | Virginia |
| Targeting PLK1 as a Common Mechanism in Ph-like ALL | University of Texas M.D. Anderson Cancer Center / Joya Chandra, PhD | Reach Grants | 2016 | Texas |
| Adoptive Immunotherapy of Tr1 Cells to Improve Outcome of Allo-HSCT Treatment for Pediatric AML | Stanford University / Maria-Grazia Roncarolo, MD & Rosa Bachetta, MD | Reach Grants | 2015 | California |
| Targeting Novel Pediatric-Specific FLT3 Mutations | Fred Hutchinson Cancer Research Center / Soheil Meshinchi, MD,PhD | Reach Grants | 2015 | Washington |
| Therapeutic Reactivation of p53 to Overcome Apoptotic Resistance in Pediatric Leukemia | Dana-Farber Cancer Institute / Loren Walensky, MD, PhD & Kimberly Stegmaier, MD | Reach Grants | 2015 | Massachusetts |
| Targeting PI3Kdelta in Childhood Acute Lymphoblastic Leukemia | Children’s Hospital Los Angeles / Yong-mi Kim, MD & Nora Heisterkamp, PhD | Reach Grants | 2015 | California |
| DNA Methylation Inhibitor Therapy for Testicular Germ Cell Tumors | University of Illinois, Urbana-Champaign / Michael Spinella, Ph.D. | Reach Grants | 2014 | Illinois |
| Targeted Inhibition of the DNA Damage Response Pathway: A Novel Intervention in the Treatment of Pediatric Leukemias | National Cancer Institute / Andre Nussenzweig, Ph.D. | Reach Grants | 2014 | Maryland |
| A Novel Target for Neuroblastoma Treatment | Beckman Research Institute of City of Hope / Linda Malkas, Ph.D. | Reach Grants | 2014 | California |
| Identifying Novel Therapeutic Combinations with 131I-MIBG to Treat Relapsed and Refractory Neuroblastoma | The Regents of the University of California San Francisco / William Clay Gustafson, M.D., Ph.D. | Reach Grants | 2014 | California |
| Identification of Rhabdomyosarcoma Therapies Using an Efficient Mouse and Drosophila Repurposing Screen | Memorial Sloan-Kettering Cancer Center / Mary Baylies, Ph.D. | Reach Grants | 2014 | New York |
| Immunotherapy for Pediatric Atypical Teratoid/Rhabdoid Tumor | Baylor College of Medicine / William Decker, PhD | Reach Grants | 2013 | Texas |
| Targeting RNA Helicase DDX3 to Treat Recurrent High Grade Sarcoma | The Johns Hopkins University School of Medicine / David Loeb, MD, PhD | Reach Grants | 2013 | Maryland |
| Stroma Biology Identifies Heparin as a Differentiating Agent in Neuroblastoma | Duke University Medical Center / Gerard Blobe, MD, PhD | Reach Grants | 2013 | North Carolina |
| B-lapachone as a Novel Targeted Therapy for ATRTs and other Pediatric Cancers | University of Texas Southwestern Medical Center / James Amatruda, MD, PhD | Reach Grants | 2013 | Texas |
| Preclinical Development of Targeted Therapy for Neuroblastoma with ALK and CDK4/6 Dual Pathway Inhibition | Children’s Hospital of Philadelphia / Yael Mossé, MD | Reach Grants | 2013 | Pennsylvania |
| Neural Stem Cell-Mediated Drug Delivery for Targeted Treatment of Medulloblastoma | Beckman Research Institute of City of Hope / Margarita Gutova, MD | Reach Grants | 2013 | California |
| Development of a Novel Mer Tyrosine Kinase Inhibitor for Treatment of ALL | University of Colorado Denver / Doug Graham, MD, PhD | Reach Grants | 2013 | Colorado |
| Epigenomics of High Risk Pediatric T Cell Leukemia | New York University School of Medicine / Iannis Aifantis, PhD | Reach Grants | 2013 | New York |
| Moving EphB4 Therapeutics to Pediatric Phase I/II Trials | Oregon Health & Science University / Charles Keller, MD | Reach Grants | 2013 | Oregon |
| Novel Strategy for Reducing Radiation-Induced Morbidity and Treating Recurrent Medulloblasoma | Massachusetts General Hospital / Rakesh Jain, PhD | Reach Grants | 2013 | Massachusetts |
| Development of a Pharmacodynamic Marker of EWS-FLI1 Activity to Aid in the Clinical Translation of Targeted Therapies for Ewing sarcoma | Van Andel Research Institute / Patrick Grohar, MD, PhD | Reach Grants | 2013 | Michigan |
| Combining Oncolytic Vaccinia Virus with GD2.CAR-modified Vaccinia Virus-specific T-cells for the Treatment of Relapsed Neuroblastoma and Sarcoma | Baylor College of Medicine / Cliona Rooney, PhD | Reach Grants | 2013 | Texas |